Why not just trust the billionaire owners of Brazilian beverage behemoth AmBev, hey? It�� about time this stock turns the corner. That is, if beer sales data from the last two months are any indicator of how the market�� been punishing AmBev simply for being Brazilian.
Sure, AmBev has been outperforming the MSCI Brazil index by a country mile, but the stock may be a victim of location. Despite the fact it�� doing better than its parent Anheuser Busch InBev by around 200 basis points, AmBev is now ranked a buy by four out of seven analysts, according to Thomson Reuters research.
The stock pays a 3.22% dividend yield and is trading below its 50 day simple moving average. It�� a little more expensive than BUD and about the same price as Boston Beer Company based on 12 month forward earnings. Only, SAM pays no dividend and BUD pays around 3%.
AmBev is more than beer. They also own the national soft drink of choice, Guaraná. Is it time for AmBev stock to outperform other big beer makers listed on the NYSE?
5 Best Healthcare Technology Stocks To Watch Right Now: Impala Platinum Holdings Ltd (IMPUY.PK)
Impala Platinum Holdings Limited (Implats) is a producer of platinum group metals (PGMs) and associated base metals. Implats has operations on the PGM-bearing orebodies of the Bushveld Complex in South Africa and the Great Dyke in Zimbabwe. PGMs include platinum, and the associated by-products, palladium, rhodium, ruthenium, iridium and gold usually occur in association with nickel and copper. As of June 30, 2012, the Company�� holdings in various mining and exploration activities included Impala Platinum Limited (100%), which includes PGM mining, processing and refining; Impala Refining Services Limited (100%), which is engaged in purchase of concentrate and/or smelter matte; Impala Chrome (Pty) Limited (100%) and Makgomo Chrome (Pty) Limited (50%), which are engaged in purchase of chrome in tailings, and Zimplats Holdings Limited (86.9%), Afplats (Pty) Limited (74%), Marula Platinum (Pty) Limited (73%), Mimosa Investments Limited (50%) and Two Rivers Platinum (Pty) Limited (45%), which are engaged in PGM mining.
Impala Platinum
Impala Platinum, Implats��primary operational unit, has operations situated on the Impala lease area on the western limb of the Bushveld Complex near Rustenburg in South Africa, and in Springs east of Johannesburg. Impala holds contiguous mining rights and prospecting rights for a total area of 260 square kilometres. Operations comprise 14 operational shaft systems, five of which have underground decline systems.
Zimplats Holdings Limited
Zimplats Holdings Limited (Zimplats) is 87% owned by Implats and is located on the Hartley Geological Complex on the Zimbabwean Great Dyke south-west of Harare. Zimplats operates three underground mines and a concentrator at Ngezi. The Selous Metallurgical Complex (SMC), located some 77 kilometer north of the mine, comprises a concentrator and a smelter. The Company also owns the Hartley Platinum Mine situated at the SMC, which is under care and maintenance.
Marula Platin! um Limited
Marula Platinum Limited (Marula) is 73% owned by Implats. Marula is located in the Limpopo Province, some 50 kilometres north of Burgersfort. The operation consists of two on-reef decline shafts, one off-reef conventional decline and a concentrator plant.
Mimosa
Mimosa is wholly owned by Mimosa Investments Limited, a Mauritius-based company jointly held by Implats and Aquarius Platinum Limited (Aquarius) in a 50:50 joint-venture. Mimosa is located on the Wedza Geological Complex on the Zimbabwean Great Dyke east of Bulawayo. The operation comprises a shallow underground mine, accessed by a decline shaft, and a concentrator.
The Two Rivers Platinum Mine
The Two Rivers Platinum Mine (Two Rivers) is a joint venture between African Rainbow Minerals (ARM) (55%) and Impala Platinum Holdings Limited (Implats) (45%). The operation is situated on the farm Dwarsrivier on the southern part of the eastern limb of the Bushveld Igneous Complex in Mpumalanga, South Africa. The operation consists of two on-reef decline shafts and a concentrator.
Impala Refining Services (IRS)
IRS products include flotation concentrates from Marula, Mimosa and Two Rivers, as well as Aquarius��Marikana, Everest mine and Blue Ridge mines (on care and maintenance) and Eastern Platinum�� Crocodile River mine; furnace matte from Zimplats; spent autocatalysts from A-1 Specialised Services and Supplies Inc. for recycling, and selected base metal residues and other secondary materials.
Advisors' Opinion:- [By Zacks Investment Research]
It is hard to find a good play in the Zacks Industry of mining non-ferrous metals, as the industry currently has a rank of 247 out of 261. In fact, in our five mining industries, there are only two No. 1-Ranked stocks: Brigus Gold (BRD) and Impala (IMPUY.PK). Both of these are in struggling industries, but they have proven to be best-in-class thanks to improving earnings estimates. Plus, both have seen their ranks surge from holds (or worse) up to strong buy territory, suggesting either of these names might be better picks than the struggling SCCO at this time.
Best Performing Companies To Buy For 2014: Hologic Inc.(HOLX)
Hologic Inc. develops, manufactures, and supplies diagnostic, medical imaging systems, and surgical products for the healthcare needs of women. The company operates in four segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment offers breast imaging products, such as Selenia full field digital mammography system, breast tomosynthesis, healthcome mammography products, screen-film mammography systems, SecurView workstation, CAD systems, stereotactic breast biopsy systems, breast biopsy products, breast brachytherapy products, MammoPad breast cushions, and photoconductor coatings, as well as Sentinelle medical MRI breast coils and workstations. This segment also develops a breast imaging platform, Dimensions, which utilizes a tomosynthesis technology to produce 3D images. The Diagnostics segment provides ThinPrep system, a solution for cervical cancer screening; rapid fetal fibronectin test for pre-term birth risk assessment; and hu man papillomavirus offering and InVitro diagnostics for cervical cancer tests. The GYN Surgical segment offers NovaSure system, a minimally-invasive procedure that allows physicians to treat women suffering from excessive menstrual bleeding; MyoSure system for the hysteroscopic removal of fibroids; and Adiana system, a form of permanent female contraception intended as an alternative to tubal ligation. The Skeletal Health segment provides QDR X-Ray bone densitometers that assess the bone density of fracture sites; Sahara clinical bone sonometers, which assess the bone density of heels; and Mini C-Arm imaging systems that are used to perform minimally invasive surgical procedures on a patient?s extremities. Hologic Inc. sells its products through a combination of direct sales and service forces, a network of independent distributors, and sales representatives primarily in the United States, Europe, and the Asia-Pacific. The company was founded in 1985 and is headquartered in Bedford, Massachusetts.
Advisors' Opinion:- [By John Udovich]
Yesterday, mid cap women�� health stock Hologic, Inc (NASDAQ: HOLX) fell more than 10% after disappointing Wall Street on earnings,�meaning it might be time to take a look at it and�small cap women�� health stocks�The Female Health Company (NASDAQ: FHCO) and TherapeuticsMD Inc (NYSEMKT: TXMD) because after all, women account for half the population and these three small caps are all focused on the women�� health:
- [By Ben Levisohn]
Intuitive Surgical has fallen 4.4% to $381.39 today, but doesn’t seem to be having much of an impact on comparable companies. Hologic (HOLX) has ticked up 0.2% to $22.06, Danaher (DHR) has fallen -.4% to $72.05 and Varian Medical Systems (VAR) has gained 0.2% to $78.70.
- [By Victor Selva]
On Nov. 11, Carl Icahn bought Hologic Inc. (HOLX), a company that develops, manufactures, and markets x-ray systems. It operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health.
Best Performing Companies To Buy For 2014: H.J. Heinz Company (HNZ)
H. J. Heinz Company manufactures and markets food products for consumers, and foodservice and institutional customers in North America, Europe, the Asia Pacific, and internationally. The company primarily offers ketchup, condiments and sauces, frozen food, soups, beans and pasta meals, infant nutrition, and other food products. It sells its products through its sales organizations, independent brokers, agents, and distributors to chain, wholesale, cooperative, and independent grocery accounts; convenience stores; bakeries; pharmacies; mass merchants; club stores; foodservice distributors; and institutions, including hotels, restaurants, hospitals, health-care facilities, and government agencies. The company was founded in 1869 and is based in Pittsburgh, Pennsylvania.
Advisors' Opinion:- [By Tim Brugger]
An investment consortium comprised of Berkshire Hathaway (NYSE: BRK-A ) and a 3G Capital investment fund has completed the acquisition of H.J. Heinz (NYSE: HNZ ) for $72.50 per share and a new CEO has taken over Heinz, the company announced today.
- [By Ploutos]
U.S. Stocks
The S&P 500 (SPY) makes a new all-time high, but closes beneath that plateau for the year. The S&P 500 eclipsed its former all-time high close of 1565 on March 28th, faster than I anticipated. With the index now ending the week above 1700 for the first time, closing below 1565 for the year seems a distant memory. Not everyone was calling for a new all-time high to be reached in 2013, and investment bank equity analysts were targeting on average high single digit annual gains at the beginning of the year. I did not expect a 19.9% return through the beginning of August, but I will take it. Grade: BThe equal-weighted S&P 500 (RSP) outperforms its capitalization-weighted alternative. The equal weighted index has produced a total return of 23.34%, besting the market capitalization-weighted S&P 500. Long-time readers know that I have long extolled the virtues of equal weighting. The lagging performance of former top holding Apple (AAPL), which has 1/14th of the weight in the equal weighted index has contributed to the outperformance of the equal weighted strategy. Grade: AThe Russell 2000 (IWM) outperforms the S&P 500 as small caps outpace large caps. The Russell 2000 has bested the S&P 500 by nearly five percent with the small cap index producing an impressive 24.8% return year-to-date. Grade: AThe shares of Bank of America (BAC) outperform J.P. Morgan (JPM) and Wells Fargo (WFC) on both an absolute and risk-adjusted basis. Bank of America has outperformed the broader market, producing a 28% total return year-to-date, but it has lagged Wells Fargo (32.1%) and J.P. Morgan (31.1%) while exhibiting higher volatility. Grade: C-The banking sector (XLF) outperforms the S&P 500. The Financial Selector Sector SPDR has produced a 27.9% year-to-date, besting the S&P 500 by roughly 8%. Grade: AHomebuilders (XHB) outperform the S&P 500, but not when adjusting for their variability of returns, which is over twice that of the broad - [By Matt Koppenheffer]
But despite the 50% stake in a joint venture to buy H. J. Heinz (NYSE: HNZ ) , which was announced recently, Berkshire's cash pile is building up again. I was hoping to hear Buffett say, "We've just bagged another "elephant."
Best Performing Companies To Buy For 2014: WisdomTree Japan Hedged Equity Fund (DXJ)
WisdomTree Japan Total Dividend Fund (The Fund) is a non-diversified fund. It seeks investment results that closely correspond to the price and yield performance, before fees and expenses, of the WisdomTree Japan Dividend Index (The Index).
The Index is a fundamentally weighted Index that measures the performance of dividend-paying companies incorporated in Japan, listed on the Tokyo Stock Exchange and that meet other requirements necessary to be included in the WisdomTree DEFA Index. The Fund is managed by WisdomTree Asset Management, Inc.
Advisors' Opinion:- [By Philip Springer, President, Retirement Wealth Management, Inc.]
The other alternative is WisdomTree Japan Hedged Equity (DXJ). As the name suggests, it's the better alternative when the yen is declining. This fund is up 23% so far in 2013, compared with 15.5% for the iShares ETF.
- [By Tom Aspray]
The recent plunge in China (FXI) puts it down 8% and even the hedged Yen Japan ETF (DXJ) has lost almost 5% in just a week or so.
In last week's column, Souring Sentiment Will Help Stocks, I discussed how the sentiment needed to become more negative in order to create a good buying opportunity. Last week's action is a step in the right direction as despite the market bullishness in December, I thought that the risk was high and that only selective buying was warranted.
Best Performing Companies To Buy For 2014: Compania de Transporte de Energia Electrica en Alta Tension Transener Sa (TRAN)
Compania de Transporte de Energia Electrica en Alta Tension Transener SA (Transener) is an Argentina-based company primarily engaged in the provision and distribution of high-voltage electric power, through its own transmission network of approximately 8,800 kilometers of transmission lines. The Company also offers such professional services as lines and substations maintenance, lines and substations operation, supervision and inspection of transmission works, as well as engineering and consulting services, among others. As of December 31, 2012, the Company had majority owned subsidaries Empresa de Transporte de Energia Electrica por Distribucion Troncal de la Provincia de Buenos Aires SA (Transba SA) and Transener Internacional Ltda. In addition, Compania Inversora en Transmision Electrica Citelec SA was its majority shareholder. Advisors' Opinion:- [By Nikolaj Gammeltoft]
U.S. stocks climbed, extending the longest winning streak for the Standard & Poor�� 500 Index (TRAN) since July, as data showed China�� economy is improving amid signs of easing tensions over Syria.
Best Performing Companies To Buy For 2014: NanoViricides Inc (NNVC)
NanoViricides, Inc., incorporated on April 1, 2005, is a development-stage company. The Company is a nano-biopharmaceutical (nanomedicine) company whose business goals are to discover, develop and commercialize therapeutics to advance the care of patients suffering from life-threatening viral infections. The Company has several drugs in various stages of early development. The Company�� drugs are based on several patents, patent applications, provisional patent applications, and other property held by TheraCour Pharma, Inc. (TheraCou), to which the Company has exclusive licenses in perpetuity for the treatment of human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Influenza including Asian Bird Flu Virus (INF), Herpes Simplex Virus (HSV), Hepatitis C Virus (HCV), Hepatitis B Virus (HBV), and Rabies. As of June 30, 2012, the Company had six drug development programs: Oral FluCideTM, against all Influenzas; a Piggy-back version of Flucide for hospitalized patients; nanoviricide eye drops against adenoviral EKC and herpes keratitis; HIVCide - I against HIV/AIDS; HerpeCide - I skin cream formulation for herpes cold sores and genital warts, and DengueCide, a broad spectrum nanoviricide designed to attack all types of dengue viruses and expected to be effective in the Severe Dengue Disease syndromes including Dengue Hemorrhagic Fever (DHS) and Dengue Shock Syndrome (DSS). As of June 30, 2012, it had engaged in organizational activities, sourcing compounds and materials, developing novel compounds and nanomaterials, and experimentation with studies on cell cultures and animals. In September 2011, NanoViricides Inc's Inno-Haven LLC acquired a light industrial building.
The Company's product development programs are divided into three sectors: commercially important diseases, neglected tropical diseases (NTD��) and biosecurity/biodefense, and advanced technologies. The Company has collaborations with KARD Scientific, Inc., MA. and Southern Research Institute, AL for influenza viruse! s; National (Central) Institute of Hygiene and Epidemiology (NIHE) (Vietnam), for H5N1 avian flu; The Long Island Jewish Medical System, Feinstein Institute of Medical Research (LIJMS), NY and TheVac, LLC. for viral diseases of the eye (adenoviruses, herpesviruses - epidemic kerato-conjunctivitis (EKC), Herpes Keratitis); TheVac, LLC and Northeastern Ohio Medical University (NEOMED) for herpes virus infections; University of California at Berkeley for dengue hemorrhagic fever viruses; Center for Disease Control and Prevention (CDC) and National (Central) Institute of Hygiene and Epidemiology for rabies virus. The Company has developed lead drug candidates against a number of viral diseases.
The Company had consolidated all of its influenza drug programs into a single pan-influenza FluCide program. It is developing a single drug for all influenzas, whether pandemic, epidemic, seasonal, novel, emerging, human, swine, or avian. It is developing a nanoviricide against adenoviral EKC. The nanoviricide eye drug candidate is formulated as simple eye drops. It is developing an anti-HSV nanoviricide skin cream formulation for direct application to the lesions. It has designed the anti-HIV nanoviricides using rational drug design principles. The ligands it has designed in the case of HIV-1 are thought to be broadly neutralizing. In-silico modeling indicates that its ligands dock to the conserved CD4 binding site of gp120 of HIV-1. The Company is working on developing anti-Dengue therapeutics. Dengue is an important NTD. Its RabiCide program has resulted in candidates that have enabled survival of 20% to 30% of infected animals after disease has set in, using a particular animal model.
The Company competes with Roche, Glaxo SmithKline, BioCryst Pharmaceuticals, Inc., Gilead, Bristol-Myers Squibb Company (BMS), Roche, Boehringer Ingelheim, Merck & Co., Inc. (Merck), Valeant, Schering, Pharmassett, Vertex, Intermune, Achillion and Novartis.
Advisors' Opinion:- [By Roberto Pedone]
One under-$10 nano-biopharmaceutical player that's starting to trend within range of triggering a big breakout trade is Nanoviricides (NNVC), which engages in the discovery, development and commercialization of anti-viral therapeutics primarily in the U.S. This stock has been ripping to the upside so far in 2013, with share up big by 198%.
If you take a look at the chart for Nanoviricides, you'll notice that this stock has recently formed a double bottom chart pattern at $4.55 to $4.52 a share. Following that bottom, shares of NNVC have now started to uptrend and move within range of triggering a big breakout trade. That trade will hit if NNVC manages to take out the upper-end of its recent sideways trading chart pattern, which has seen NNVC trend between $4.55 and $5.74 a share.
Traders should now look for long-biased trades in NNVC if it manages to break out above some near-term overhead resistance levels at Friday's high of $4.94 a share to its 50-day moving average of $5.28 a share, and then once it takes out some more key overhead resistance levels at $5.72 to $5.74 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average volume of 234,994 shares. If that breakout triggers soon, then NNVC will set up to re-test or possibly take out its next major overhead resistance levels at $6.50 to its 52-week high at $7.59 a share.
Traders can look to buy NNVC off weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $4.55 to $4.52 a share. One can also buy NNVC off strength once it starts to clear those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
No comments:
Post a Comment